$19.18
0.05% yesterday
NYSE, Sep 27, 10:10 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$19.18
-3.23 14.41% 1M
+0.73 3.96% 6M
+4.76 33.01% YTD
+2.59 15.61% 1Y
-14.36 42.81% 3Y
-14.07 42.32% 5Y
-14.07 42.32% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.01 0.05%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $4.94b
Enterprise Value $12.89b
P/E (TTM) P/E ratio 4.93
EV/FCF (TTM) EV/FCF 15.09
EV/Sales (TTM) EV/Sales 2.03
P/S ratio (TTM) P/S ratio 0.78
P/B ratio (TTM) P/B ratio 34.28
Dividend yield 5.84%
Last dividend (FY23) $1.12
Revenue growth (TTM) Revenue growth 2.89%
Revenue (TTM) Revenue $6.35b
EBIT (operating result TTM) EBIT $1.34b
Free Cash Flow (TTM) Free Cash Flow $854.00m
Cash position $704.00m
EPS (TTM) EPS $3.89
P/E forward 5.09
P/S forward 0.77
EV/Sales forward 2.02
Short interest 4.04%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Organon & Co. forecast:

4x Buy
40%
4x Hold
40%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a Organon & Co. forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
6,346 6,346
3% 3%
100%
- Direct Costs 2,628 2,628
12% 12%
41%
3,718 3,718
3% 3%
59%
- Selling and Administrative Expenses 1,623 1,623
6% 6%
26%
- Research and Development Expense 499 499
5% 5%
8%
1,596 1,596
9% 9%
25%
- Depreciation and Amortization 252 252
13% 13%
4%
EBIT (Operating Income) EBIT 1,344 1,344
13% 13%
21%
Net Profit 1,000 1,000
33% 33%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Positive
Barrons
9 days ago
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Positive
Reuters
10 days ago
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Neutral
Business Wire
10 days ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today